Delivery Order SPE2DB25D3007-SPE2DB25FWSUN
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $13,364.72 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets in quantities of 30 units. This firm fixed price, competitively awarded contract was issued on July 21, 2025, with an ultimate completion date of July 22, 2025. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,931.68 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 4, 2025, with completion scheduled for August 5, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The pharmaceutical distributor,...
- The Defense Logistics Agency awarded a $42,773.33 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is listed...
- The Defense Logistics Agency awarded a delivery order valued at $6,665.61 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) with a firm fixed price structure. The contract was competitively awarded without a set-aside designation and is scheduled for ultimate completion by June 20, 2025. This delivery order is placed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive...
- The Defense Logistics Agency awarded a $80,832.18 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract involves no set-aside...
- The Defense Logistics Agency awarded a $18,669.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $30,275.00 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 15, 2025, with an ultimate completion date of August 18, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be performed...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for RINVOQ ER 15 mg tablets (30-unit bottles) under a firm fixed-price contract valued at $10,362.56. This is a non-set-aside competitive award with an ultimate completion date of July 30, 2025. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical support vehicle...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $15,354.11 to AmerisourceBergen Drug Corp for RINVOQ ER 30 MG tablets (30-tablet units) on September 11, 2025, with completion scheduled for September 12, 2025. This competitively awarded, firm fixed price delivery order represents a non-set-aside procurement and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child order under a larger vehicle, this...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) valued at $9,780.29 under a firm fixed-price contract type. The award, made on August 19, 2025, with an ultimate completion date of August 20, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate...
- SPE2DB25D3007Indefinite Delivery Contract
- SPE2DB25D3007-SPE2DB25FWSUNDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,170.21 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count package) with an ultimate completion date of September 8, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is executed as a delivery order under AmerisourceBergen's larger prime contract vehicle with DLA. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations for federal medical procurement. This delivery order is a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical supply chains, AmerisourceBergen regularly fulfills defense and veteran healthcare needs through this comprehensive global pharmaceutical support vehicle. The company's contract portfolio with DLA demonstrates consistent capability to deliver specialized medications across multiple therapeutic domains to support military healthcare programs, making this RINVOQ order representative of the company's routine operations supporting the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.2k | 9/5/25 |